No Data
Hualan biological engineering, inc. (002007.SZ): The application for registration of rituximab injection has been accepted.
Hualan Biological Engineering, Inc. (002007.SZ) announced that its affiliated company Hualan Genetic Engineering Co., Ltd. has received notification from the national pharmaceutical regulatory authority...
Hualan Biological Engineering's Unit Gets Certificate for Cancer Drug's Registration
Express News | Hualan biological engineering, inc.: The gene company has obtained the registration certificate for the pharmaceutical Bevacizumab Injection.
Hualan Biological Engineering, Inc.: Third quarter report of 2024.
hualan biological engineering, inc. (002007.SZ) released its performance for the first three quarters, with a net income of 0.924 billion yuan, a year-on-year decrease of 13.46%.
hualan biological engineering, inc. (002007.SZ) released the third quarter report for 2024, achieving revenue in the first three quarters...
Hualan Biological Engineering, Inc. (002007): Stable growth of blood products, influenza vaccines expected to be traded for quantity at a price.
Executive summary of this report: The company's performance in Q2 2024 showed strong recovery compared to the previous quarter, with the expected maintenance of high-speed growth in plasma collection and the potential for trading price for volume in vaccines, maintaining a shareholding rating. Investment highlights: Maintaining a shareholding rating. Taking into account the impact of the price reduction of influenza vaccines, a downward adjustment of 2
No Data
No Data